Showing results (111-120 of 137) with videos related to
Sort By:
Pageof 14
Advances in Therapy|October 29, 2024
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated CirrhosisMarkus Cornberg, Dietrich Hüppe, Christoph Sarrazin, et al.Alimentary Pharmacology & Therapeutics|March 25, 2021
Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitisPierre-Antoine Soret, Laurent Lam, Fabrice Carrat, et al.Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.Journal of Hepatology|July 26, 2011
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 studyJean-Pierre Zarski, Nathalie Sturm, Jérôme Guechot, et al.BMC Infectious Diseases|April 4, 2019
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohortAnne Laurain, Sophie Metivier, Georges Haour, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 10, 2023
Diagnosis and management of hepatic encephalopathy: The French recommendationsDominique Thabut, Charlotte Bouzbib, Lucy Meunier, et al.The New England Journal of Medicine|June 7, 2018
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary CholangitisChristophe Corpechot, Olivier Chazouillères, Alexandra Rousseau, et al.Journal of Hepatology|September 14, 2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsStanislas Pol, Marc Bourliere, Sandy Lucier, et al.Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort studyLaurent Lam, Hélène Fontaine, Marc Bourliere, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|April 15, 2021
Large-scale screening of lipase acid deficiency in at risk populationAbdellah Tebani, Bénédicte Sudrié-Arnaud, Hela Boudabous, et al.Pageof 14